Autopsy report · NCT01758289

Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients

“Changes in country regulation”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 10 months before it stopped.
• 105 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Sponsor

AbbVie (prior sponsor, Abbott)

Sponsor type

Industry

Conditions

Chronic Kidney Disease Stage V; Hemodialysis

Participants

105

Sites

8

Countries

Venezuela

Trials that died the same way

• Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
  “Because the implementation of the new regulation policy by the Chinese authority” (57% match in meaning)
• Very Small Embryonic-like Stem Cells for Erectile Dysfunction
  “Policy changes have contributed to the failure to carry out smoothly” (56% match in meaning)
• TC02 Obese Women Using It Morphine vs PCA IV Hydromorphone for Post-Cesarean Analgesia
  “Change in institutional policy. Change in resources available.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.